09:45:09 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-13 Kvartalsrapport 2024-Q3
2024-08-21 Kvartalsrapport 2024-Q2
2024-05-15 Kvartalsrapport 2024-Q1
2024-03-21 X-dag ordinarie utdelning HLUN A 0.70 DKK
2024-03-21 X-dag ordinarie utdelning HLUN B 0.70 DKK
2024-03-20 Årsstämma 2024
2024-02-07 Bokslutskommuniké 2023
2023-11-08 Kvartalsrapport 2023-Q3
2023-08-16 Kvartalsrapport 2023-Q2
2023-05-10 Kvartalsrapport 2023-Q1
2023-03-22 X-dag ordinarie utdelning HLUN A 0.58 DKK
2023-03-22 X-dag ordinarie utdelning HLUN B 0.58 DKK
2023-03-21 Årsstämma 2023
2023-02-08 Bokslutskommuniké 2022
2022-11-09 Kvartalsrapport 2022-Q3
2022-08-17 Kvartalsrapport 2022-Q2
2022-06-10 Split HLUN B 1:5
2022-06-08 Extra Bolagsstämma 2022
2022-05-11 Kvartalsrapport 2022-Q1
2022-03-24 X-dag ordinarie utdelning HLUN B 2.00 DKK
2022-03-23 Årsstämma 2022
2022-02-09 Bokslutskommuniké 2021
2021-11-10 Kvartalsrapport 2021-Q3
2021-08-18 Kvartalsrapport 2021-Q2
2021-05-11 Kvartalsrapport 2021-Q1
2021-03-24 X-dag ordinarie utdelning HLUN B 2.50 DKK
2021-03-23 Årsstämma 2021
2021-02-04 Bokslutskommuniké 2020
2020-11-03 Kvartalsrapport 2020-Q3
2020-08-13 Kvartalsrapport 2020-Q2
2020-05-12 Kvartalsrapport 2020-Q1
2020-03-25 X-dag ordinarie utdelning HLUN B 4.10 DKK
2020-03-24 Årsstämma 2020
2020-02-06 Bokslutskommuniké 2019
2019-11-05 Kvartalsrapport 2019-Q3
2019-08-14 Kvartalsrapport 2019-Q2
2019-05-08 Kvartalsrapport 2019-Q1
2019-03-27 X-dag ordinarie utdelning HLUN B 12.00 DKK
2019-03-26 Årsstämma 2019
2019-02-05 Bokslutskommuniké 2018
2018-11-07 Kvartalsrapport 2018-Q3
2018-08-08 Kvartalsrapport 2018-Q2
2018-05-08 Kvartalsrapport 2018-Q1
2018-03-21 X-dag ordinarie utdelning HLUN B 8.00 DKK
2018-03-20 Årsstämma 2018
2018-02-07 Bokslutskommuniké 2017
2017-11-08 Kvartalsrapport 2017-Q3
2017-08-09 Kvartalsrapport 2017-Q2
2017-05-10 Kvartalsrapport 2017-Q1
2017-03-31 X-dag ordinarie utdelning HLUN B 2.45 DKK
2017-03-30 Årsstämma 2017
2017-02-08 Bokslutskommuniké 2016
2016-11-02 Kvartalsrapport 2016-Q3
2016-08-24 Kvartalsrapport 2016-Q2
2016-05-11 Kvartalsrapport 2016-Q1
2016-04-01 X-dag ordinarie utdelning HLUN B 0.00 DKK
2016-03-31 Årsstämma 2016
2016-02-10 Bokslutskommuniké 2015
2015-11-04 Kvartalsrapport 2015-Q3
2015-08-19 Kvartalsrapport 2015-Q2
2015-05-06 Kvartalsrapport 2015-Q1
2015-03-26 X-dag ordinarie utdelning HLUN B 0.00 DKK
2015-03-25 Årsstämma 2015
2015-02-05 Bokslutskommuniké 2014
2014-11-05 Kvartalsrapport 2014-Q3
2014-08-07 Kvartalsrapport 2014-Q2
2014-05-07 Kvartalsrapport 2014-Q1
2014-03-27 X-dag ordinarie utdelning HLUN B 2.77 DKK
2014-03-26 Årsstämma 2014
2014-02-06 Bokslutskommuniké 2013
2013-11-06 Kvartalsrapport 2013-Q3
2013-08-07 Kvartalsrapport 2013-Q2
2013-05-01 Kvartalsrapport 2013-Q1
2013-03-22 X-dag ordinarie utdelning HLUN B 2.00 DKK
2013-03-21 Årsstämma 2013
2013-02-06 Bokslutskommuniké 2012
2012-11-07 Kvartalsrapport 2012-Q3
2012-08-08 Kvartalsrapport 2012-Q2
2012-05-02 Kvartalsrapport 2012-Q1
2012-03-30 X-dag ordinarie utdelning HLUN B 3.49 DKK
2012-03-29 Årsstämma 2012
2012-02-08 Bokslutskommuniké 2011
2011-11-09 Kvartalsrapport 2011-Q3
2011-08-10 Kvartalsrapport 2011-Q2
2011-05-04 Kvartalsrapport 2011-Q1
2011-03-31 X-dag ordinarie utdelning HLUN B 3.77 DKK
2011-03-30 Årsstämma 2011
2010-04-21 X-dag ordinarie utdelning HLUN B 3.07 DKK
2009-04-22 X-dag ordinarie utdelning HLUN B 2.30 DKK

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriLäkemedel & Handel
Lundbeck är ett läkemedelsbolag. Störst fokus återfinns inom forskning om psykiatriska och neurotiska störningar, vilket innefattar behandling av depression, schizofreni, Alzheimers och Parkinsons syndrom. Bolaget bedriver forskning, utveckling och distribution av läkemedel där kundbasen återfinns på global nivå. Bolaget grundades ursprungligen under 1915 och har sitt huvudkontor i Valby.
2024-03-05 09:00:00

The AMULET trial strengthens the case for Lundbeck's Lu AF82422, as initial clinical data suggests that the anti-alpha-synuclein monoclonal antibody (mAb) has a potential to slow clinical progression.

H. Lundbeck A/S (Lundbeck) announces clinical data from the AMULET phase II, double-blind, randomized trial of Lu AF82422 in Multiple System Atrophy (MSA) at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD 2024) on March 8, 2024, in Lisbon, Portugal. The presentation will start at 4:35 PM CET.

Lu AF82422 is a human monoclonal antibody (mAb) that recognizes and binds to all major forms of extracellular alpha-synuclein and thereby is believed to prevent uptake and inhibit seeding of aggregation.

Lu AF82422 may offer a potential treatment option by targeting the underlying disease pathology of MSA and aiming at slowing clinical progression.

Based on the encouraging AMULET trial outcomes, Lundbeck plans to initiate a phase III study, following further dialogue with health authorities.

"We are excited to be presenting data that advances a possible option for addressing a significant unmet need. We are looking forward to further understanding the potential of this program for the benefit of MSA patients," said Johan Luthman, EVP, and Head of Research & Development at Lundbeck.

Scientific presentation from Lundbeck at AD/PD 2024

Supportive results from the AMULET phase 2, double-blind, randomized trial of Lu AF82422 in multiple system atrophy.
  • AMULET (NCT05104476) was a double-blind, placebo-controlled trial investigating the safety and efficacy of monthly IV infusions with Lu AF82422 in patients with MSA.
  • 61 participants were treated with Lu AF82422 (n=40) or placebo (n=21).
  • The primary endpoint showed a non-statistically significant 19% slowing of clinical progression measured by UMSARS Total Score (UMSARS Part I + Part II) in the Lu AF82422 group vs placebo.
  • The slope analysis of mUMSARS, UMSARS part I and part II showed a consistent slowing in clinical progression of 27%, 22% and 17%, respectively.
  • A trend towards smaller regional MRI volumetric reduction in the Lu AF82422 group vs placebo was also observed.
  • Lu AF82422 was generally well tolerated.

Lundbeck is grateful to all the trial participants, and the investigators who contributed greatly to this research.

About the AMULET trial
AMULET trial was a phase II, randomized, double-blind, placebo-controlled clinical trial of Lu AF82422 as a potential treatment for patients with MSA. A total of N=61 MSA patients were randomized 2:1 to either Lu AF82422 or placebo and treated between 48 to 72 weeks, followed by an ongoing 48 weeks open-label extension period offering all participants to receive treatment with Lu AF82422.

The primary objective was to evaluate the efficacy of Lu AF82422 on clinical progression in patients with MSA, aiming at showing a slowing in clinical progression in the active treatment arm compared to placebo on a 5% significance level evaluated 1-sided as well as safety and tolerability. The secondary objectives included evaluation of Lu AF82422 on patient's functioning, disease severity and other aspects of MSA.

Lu AF82422 was delivered as an intravenous infusion every four weeks.

About Lu AF82422
Lu AF82422 is a human monoclonal antibody (mAb) that recognizes and binds to all major forms of extracellular α-syn and thereby is believed to prevent uptake and inhibit seeding of aggregation. Lu AF82422 has an active Fc region, which may increase immune-mediated clearance of α-syn/mAb complexes through microglia mediated uptake. Lu AF82422 is being developed by Lundbeck under a joint research and licensing agreement between Lundbeck and Genmab A/S.

About Multiple System Atrophy
MSA is a rapidly progressing rare condition of the nervous system that causes damage to nerve cells in the brain. MSA is seriously debilitating and places a high disease burden on patients. Symptoms of MSA usually start between 55 and 60 years of age and the patients typically live for 6 to 9 years after symptom onset[1].

In a person with MSA, an abnormal build-up of the protein alpha-synuclein is thought to be responsible for damaging areas of the brain that control balance, movement, and the body's normal functions[1]. The symptoms of MSA are wide-ranging and include muscle control problems, similar to those of Parkinson's disease[1]. Many different functions of the body can be affected, and symptoms including urinary incontinence, frequent falling, and unintelligible speech occur within 3 years of disease onset and are accompanied by reduced capacity to live independently. Death is often due to respiratory problems. Although there are many different possible symptoms of MSA, not everyone who is affected will experience all of them. There is currently no cure for MSA and no available treatment to slow its progression[1].

References:

1 - NHS: Multiple system atrophy - NHS (www.nhs.uk)

H. Lundbeck A/S (Lundbeck)

Contacts

Thomas Mikkel Palle Holm Olesen
Mortensen
Media Relations Vice President, Investor Relations
Lead, Corp.
Communication
THMR@lundbeck.com PALO@lundbeck.com (PALO@lundbeck.com)
+45 30 83 30 24 +45 30 83 24 26
Sophia Nørskov BechSenior
Manager, Investor
Relations
SONQ@lundbeck.com
+45 30 83 24 60

About H. Lundbeck A/S
Lundbeck is a biopharmaceutical company focused exclusively on neuroscience, with more than 70 years of experience in improving the lives of people with neurological and psychiatric diseases.

As a focused innovator, we strive for our research and development programs to tackle some of the most complex challenges. We develop transformative medicines targeting people for whom there are few, if any, treatment options.

Our goal is to create long term value and make a positive contribution to people and societies, everywhere we operate. We are committed to fighting stigma and discrimination, and we act to improve health equity for the people we serve and the communities we are part of. 

For additional information, we encourage you to visit our corporate site www.lundbeck.com (https://www.lundbeck.com/global) and connect with us via LinkedIn (https://www.linkedin.com/company/lundbeck/).